SCYNEXIS (SCYX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic focus

• Focuses on developing therapies for orphan conditions and severe rare diseases, leveraging expertise in specialized hospital and healthcare center engagement.

• Recently expanded portfolio with the acquisition of SCY-770 for autosomal dominant polycystic kidney disease (ADPKD), complementing existing antifungal assets.

• Both main assets target conditions with significant unmet medical need and limited treatment options.

Recent milestones and upcoming catalysts

• Two phase I studies are concluding: one for SCY-770 in ADPKD and another for an intravenous antifungal agent.

• Phase II study in ADPKD is set to begin by year-end, with an interim efficacy readout expected in the second half of next year.

• Dose selection for phase II is driven by pharmacokinetic data and preclinical efficacy targets.

Rationale and details of SCY-770 acquisition

• SCY-770 was acquired for $8 million upfront, with up to $8 million in development milestones and $180 million in commercial milestones.

• The asset's advanced development stage and compelling mechanism as an AMPK activator were key factors in the acquisition.

• Intellectual property includes patents extending to 2042 and orphan drug exclusivity.